Ak, M. A. Et Al. 2022. The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.2 , 299-308.

Ak, M. A., Sahip, B., GEDÜK, A., Ucar, M. A., Kale, H., Hacibekiroglu, T., ... POLAT, M. G.(2022). The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.2, 299-308.

Ak, Muzeyyen Et Al. "The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study," INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.2, 299-308, 2022

Ak, Muzeyyen A. Et Al. "The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study." INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.2, pp.299-308, 2022

Ak, M. A. Et Al. (2022) . "The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study." INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.2, pp.299-308.

@article{article, author={Muzeyyen Aslaner Ak Et Al. }, title={The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study}, journal={INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION}, year=2022, pages={299-308} }